Jess Stoodley
DPhil Student and Research Assistant
I joined the Wood group in 2018 as a research assistant working on developing therapies for Spinal Muscular Atrophy. I have since started a PhD, working on testing treatments for Myotonic Dystrophy 1, with a focus is on using antibody and peptide antisense oligonucelotide conjugates.
Recent publications
-
PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice.
Journal article
Kordala AJ. et al, (2023), EMBO Mol Med, 15
-
Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.
Journal article
Stoodley J. et al, (2023), Int J Mol Sci, 24
-
Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy.
Journal article
Stoodley J. et al, (2023), Methods Mol Biol, 2587, 209 - 237
-
Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy.
Journal article
Hammond SM. et al, (2022), JCI Insight, 7
-
Evaluating Efficacy of Peptide-Delivered Oligonucleotides Using the Severe Taiwanese SMA Mouse Model.
Chapter
Goli L. et al, (2022), 2383, 491 - 513